Keywords: Novartis, Afinitor, Advanced breast cancer, USA, FDA

FDA backs Novartis' Afinitor for advanced breast cancer

Article | 23 July 2012

Print This

There was good news for Swiss drug major Novartis (NOVN: VX) on Friday, when the US Food and Drug Administration ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in